Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) Operating Expenses (2018 - 2025)

Historic Operating Expenses for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to $20.7 million.

  • Precision Biosciences' Operating Expenses fell 535.9% to $20.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.2 million, marking a year-over-year decrease of 120.7%. This contributed to the annual value of $94.9 million for FY2024, which is 259.02% up from last year.
  • Per Precision Biosciences' latest filing, its Operating Expenses stood at $20.7 million for Q3 2025, which was down 535.9% from $21.9 million recorded in Q2 2025.
  • In the past 5 years, Precision Biosciences' Operating Expenses ranged from a high of $47.2 million in Q2 2021 and a low of $20.7 million during Q3 2025
  • Over the past 5 years, Precision Biosciences' median Operating Expenses value was $22.9 million (recorded in 2023), while the average stood at $27.1 million.
  • Per our database at Business Quant, Precision Biosciences' Operating Expenses surged by 3921.09% in 2021 and then crashed by 3873.4% in 2022.
  • Over the past 5 years, Precision Biosciences' Operating Expenses (Quarter) stood at $37.1 million in 2021, then plummeted by 38.73% to $22.7 million in 2022, then dropped by 3.43% to $21.9 million in 2023, then grew by 16.22% to $25.5 million in 2024, then decreased by 18.85% to $20.7 million in 2025.
  • Its Operating Expenses stands at $20.7 million for Q3 2025, versus $21.9 million for Q2 2025 and $22.1 million for Q1 2025.